This study examined the effects of the novel prostate cancer treatment [¹⁷⁷Lu]Lu-PSMA-617 on clonal hematopoiesis, an age-related accumulation of mutations in blood cells. In patients with advanced prostate cancer, 177Lu-PSMA-617 was associated with a higher rate of new CH mutations compared to standard chemotherapy, particularly in genes involved in DNA repair. While the long-term implications remain unclear, these findings suggest that radioligand therapy may influence blood cell biology as it is used earlier in treatment.

See abstract in Journal of Clinical Oncology. 

See press coverage by Anzup.